ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M
ChemoCentryx press release  (NASDAQ:CCXI): Q2  GAAP EPS of -$0.44  misses by $0.03.
Revenue of $11.76M (+553.3% Y/Y)  misses by $9.89M.
On August 3, 2022, the company entered into merger deal with Amgen under which Amgen will acquire the Company for $52.00 per share in cash, representing an enterprise value of approximately $3.7 billion.
The transaction is subject to the company's stockholder approval, regulatory approvals and other customary closing conditions, and is expected to close in the fourth quarter of 2022.
Also Read: Amgen posts 2Q beat, trims earnings guidance; new drugs outperform